MedTrace Logo

Study Evaluating the Gastrointestinal Safety of PLA-695 Compared to Placebo and Naproxen

NCT00366262 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL

Last updated 2008-08-05

No results posted yet for this study

Summary

The purpose of this study is to provide an initial assessment of the gastrointestinal safety of a 7-day regimen of PLA-695 compared to placebo or naproxen.

Conditions

  • Healthy

Interventions

DRUG

PLA-695

DRUG

Naproxen

DRUG

Placebo

Sponsors & Collaborators

  • Wyeth is now a wholly owned subsidiary of Pfizer

    lead INDUSTRY

Principal Investigators

  • Medical Monitor · Wyeth is now a wholly owned subsidiary of Pfizer

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2006-06-30
Completion
2007-03-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00366262 on ClinicalTrials.gov